NeuroXense

Develops a pre-clinical, tear-based Parkinson's diagnostic platform and a personalised follow-up model.

ShareLink copied

The record

Vertical
Imaging & Diagnostics
Sub-segment
Parkinson's biomarkers
Product type
Diagnostics
Stage
Pre-seed
Headquarters
Argentina
Region
Latin America
Pre-seed round being raised
US$200,000 to US$250,000
Company says. November 2026. Source

What they do

NeuroXense is an Argentina-based company developing a non-invasive diagnostic platform for Parkinson's disease based on tear samples. Its proprietary aptamer-based approach is intended to detect biomarkers, with a machine learning model for personalised follow-up. The work is pre-clinical, and the company says its next step in 2027 is working with real tears from patients. Its business model is B2B2B. Camila Feltrin is co-founder and CEO.

History and progression

How NeuroXense got here, step by step.

  1. 12 November 2026

    PITCH semi-final

    NeuroXense was one of nine startups in the PITCH semi-final on Centre Stage at Web Summit Lisbon 2026. It did not reach the final.

    Web Summit appearance

Sources and coverage

  1. November 2026

    Web Summit: NeuroXense appearance and pre-seed fundraising
  2. 15 November 2026

    The HealthTech Signal: Web Summit 2026 health tech

Related companies

Is this your company? Feature it